Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal homeostasis by inducing mucosal protective factors

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Kawahara, Tomohiro ^a   Makizaki, Yutaka ^a   Oikawa, Yosuke ^a   Tanaka, Yoshiki ^a   Maeda, Ayako ^a   Shimakawa, Masaki ^a   Komoto, Satoshi ^b   Moriguchi, Kyoko ^b   Ohno, Hiroshi ^a   Taniguchi, Koki ^b  

^a Research and Development Department   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 1; MUCIN 2; MUCIN 3; MUCIN 4; OCCLUDIN; PROBIOTIC AGENT; SODIUM GLUCOSE COTRANSPORTER 1; TRANSFORMING GROWTH FACTOR BETA1; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; VILLIN; VILLIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIARRHEAL ACTIVITY; ARTICLE; BIFIDOBACTERIUM BIFIDUM; CECUM; CELL COUNT; CELL SIZE; CELL VACUOLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; FECES ANALYSIS; GENE EXPRESSION; GOBLET CELL; HOMEOSTASIS; INFECTION PREVENTION; INTESTINE INJURY; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; INTESTINE VILLUS; MOUSE; NONHUMAN; REGULATORY MECHANISM; ROTAVIRUS INFECTION; SMALL INTESTINE EPITHELIUM; SUCKLING ANIMAL; TREATMENT DURATION; VIRAL GASTROENTERITIS; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHLOROCEBUS AETHIOPS; COMPLICATION; GASTROENTERITIS; GENE EXPRESSION REGULATION; INTESTINE; ISOLATION AND PURIFICATION; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY; RHESUS MONKEY; ROTAVIRUS; ROTAVIRUS INFECTIONS;

ADMINISTRATION, ORAL; ANIMALS; BIFIDOBACTERIUM BIFIDUM; CELL LINE; CERCOPITHECUS AETHIOPS; DIARRHEA; GASTROENTERITIS; GENE EXPRESSION REGULATION; INTESTINES; MACACA MULATTA; MICE, INBRED BALB C; PROBIOTICS; ROTAVIRUS; ROTAVIRUS INFECTIONS;

EID: 85016314455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0173979     Document Type: Article

References (52)

1. Tate JE, Steele AD, Bines JE, Zuber PL, Parashar UD. Research priorities regarding rotavirus vaccine and intussusception: A meeting summary. Vaccine. 2012; 30 Suppl 1: A179-184.
2. Morris AP, Estes MK. Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VIII. Pathological consequences of rotavirus infection and its enterotoxin. Am J Physiol Gastrointest Liver Physiol. 2001; 281: G303-310.
3. Lundgren O, Peregrin AT, Persson K, Kordasti S, Uhnoo I, et al. Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea. Science. 2000; 287: 491-495.
4. Babji S, Kang G. Rotavirus vaccination in developing countries. Curr Opin Virol. 2012; 2: 443-448. https://doi.org/10.1016/j.coviro.2012.05.005
5. Parashar UD, Johnson H, Steele AD, Tate JE. Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward. Clin Infect Dis. 2016; 62 Suppl 2: S91-95.
6. O'Ryan ML, Pena A, Vergara R, Diaz J, Mamani N, Cortes H, et al. Prospective characterization of norovirus compared with rotavirus acute diarrhea episodes in chilean children. Pediatr Infect Dis J. 2010; 29: 855-859. https://doi.org/10.1097/INF.0b013e3181e8b346
7. Vandenplas Y. Probiotics and prebiotics in infectious gastroenteritis. Best Pract Res Clin Gastroenterol. 2016; 30: 49-53. https://doi.org/10.1016/j.bpg.2015.12.002
8. FAO/WHO. The joint FAO/WHO Expert Consultation on Evaluation of Health and Nutrition Properties of Probiotics in food held in CoÂrdoba, Argentina from 1-4 October, 2001. FAO, Rome and WHO, Geneva
9. Ahmadi E, Alizadeh-Navaei R, Rezai MS. Efficacy of probiotic use in acute rotavirus diarrhea in children: A systematic review and meta-Analysis. Caspian J Intern Med. 2015; 6: 187-195.
10. Vandenplas Y, De Greef E, Devreker T, Veereman-Wauters G, Hauser B. Probiotics and prebiotics in infants and children. Curr Infect Dis Rep. 2013; 15: 251-262. https://doi.org/10.1007/s11908-013-0334-4
11. Xiao JZ, Takahashi S, Nishimoto M, Odamaki T, Yaeshima T, Iwatsuki K, et al. Distribution of in vitro fermentation ability of lacto-N-biose I, a major building block of human milk oligosaccharides, in bifidobacterial strains. Appl Environ Microbiol. 2010; 76: 54-59. https://doi.org/10.1128/AEM.01683-09
12. Tsunemine S, Isa Y, Shimakawa M, Ohno H, Yamamura H. Effects of Bifidobacterium bifidum G9-1 on Nasal Symptoms in a Guinea Pig Model of Experimental Allergic Rhinitis. Biosci Microflora. 2011; 30: 1-7. https://doi.org/10.12938/bifidus.30.1
13. Tsunemine S, Isa Y, Ohno H, Hagino S, Yamamura H, Mizutani N, et al. (2015) Longitudinal study of effects of oral dosage of Bifidobacterium bifidum G9-1 on Japanese cedar pollen-induced allergic nasal symptoms in guinea pigs. Microbiol Immunol. 2015/09/25 ed. pp. 690-699. https://doi.org/10.1111/1348-0421.12324
14. Ohno H, Tsunemine S, Isa Y, Shimakawa M, Yamamura H. Oral administration of Bifidobacterium bifidum G9-1 suppresses total and antigen specific immunoglobulin E production in mice. Biol Pharm Bull. 2005; 28: 1462-1466.
15. Duffy LC, Zielezny MA, Riepenhoff-Talty M, Dryja D, Sayahtaheri-Altaie S, Griffiths E, et al. Effectiveness of Bifidobacterium bifidum in mediating the clinical course of murine rotavirus diarrhea. Pediatr Res. 1994; 35: 690-695. https://doi.org/10.1203/00006450-199406000-00014
16. Guerin-Danan C, Meslin JC, Chambard A, Charpilienne A, Relano P, Bouley C, et al. Food supplementation with milk fermented by Lactobacillus casei DN-114 001 protects suckling rats from rotavirus-Associated diarrhea. J Nutr. 2001; 131: 111-117.
17. Qiao H, Duffy LC, Griffiths E, Dryja D, Leavens A, Rossman J, et al. Immune responses in rhesus rotavirus-challenged BALB/c mice treated with bifidobacteria and prebiotic supplements. Pediatr Res. 2002; 51: 750-755. https://doi.org/10.1203/00006450-200206000-00015
18. Azevedo MS, Zhang W, Wen K, Gonzalez AM, Saif LJ, Yousef AE, et al. Lactobacillus acidophilus and Lactobacillus reuteri modulate cytokine responses in gnotobiotic pigs infected with human rotavirus. Benef Microbes. 2012; 3: 33-42. https://doi.org/10.3920/BM2011.0041
19. Gagnon M, Vimont A, Darveau A, Fliss I, Jean J. Study of the Ability of Bifidobacteria of Human Origin to Prevent and Treat Rotavirus Infection Using Colonic Cell and Mouse Models. PLoS One. 2016; 11: e0164512. https://doi.org/10.1371/journal.pone.0164512
20. Zhang Z, Xiang Y, Li N, Wang B, Ai H, Wang X, et al. Protective effects of Lactobacillus rhamnosus GG against human rotavirus-induced diarrhoea in a neonatal mouse model. Pathog Dis. 2013; 67: 184-191. https://doi.org/10.1111/2049-632X.12030
21. Komoto S, Sasaki J, Taniguchi K. Reverse genetics system for introduction of site-specific mutations into the double-stranded RNA genome of infectious rotavirus. Proc Natl Acad Sci U S A. 2006; 103: 4646-4651. https://doi.org/10.1073/pnas.0509385103
22. Riepenhoff-Talty M, Offor E, Klossner K, Kowalski E, Carmody PJ, et al. Effect of age and malnutrition on rotavirus infection in mice. Pediatr Res. 1985; 19: 1250-1253.
23. Wolber FM, Broomfield AM, Fray L, Cross ML, Dey D. Supplemental dietary whey protein concentrate reduces rotavirus-induced disease symptoms in suckling mice. J Nutr. 2005; 135: 1470-1474.
24. Knipping K, McNeal MM, Crienen A, van Amerongen G, Garssen J, et al. A gastrointestinal rotavirus infection mouse model for immune modulation studies. Virol J. 2011; 8: 109. https://doi.org/10.1186/1743-422X-8-109
25. Hernandez PP, Mahlakoiv T, Yang I, Schwierzeck V, Nguyen N, Guendel F, et al. Interferon-λ and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat Immunol. 2015; 16: 698-707. https://doi.org/10.1038/ni.3180
26. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA gene-Targeted group-specific primers for real-Time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol. 2004; 70: 7220-7228. https://doi.org/10.1128/AEM.70.12.7220-7228.2004
27. Boshuizen JA, Reimerink JH, Korteland-van Male AM, van Ham VJ, Koopmans MP, Buller HA, et al. Changes in small intestinal homeostasis, morphology, and gene expression during rotavirus infection of infant mice. J Virol. 2003; 77: 13005-13016. https://doi.org/10.1128/JVI.77.24.13005-13016.2003
28. Chen CC, Baylor M, Bass DM. Murine intestinal mucins inhibit rotavirus infection. Gastroenterology. 1993; 105: 84-92.
29. Boshuizen JA, Reimerink JH, Korteland-van Male AM, van Ham VJ, Bouma J, Gerwig GJ, et al. Homeostasis and function of goblet cells during rotavirus infection in mice. Virology. 2005; 337: 210-221. https://doi.org/10.1016/j.virol.2005.03.039
30. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999; 276: G941-950.
31. Khatri IA, Ho C, Specian RD, Forstner JF. Characteristics of rodent intestinal mucin Muc3 and alterations in a mouse model of human cystic fibrosis. Am J Physiol Gastrointest Liver Physiol. 2001; 280: G1321-1330.
32. Lopez S, Arias CF. Multistep entry of rotavirus into cells: A Versaillesque dance. Trends Microbiol. 2004; 12: 271-278. https://doi.org/10.1016/j.tim.2004.04.003
33. Willoughby RE. Rotaviruses preferentially bind O-linked sialylglycoconjugates and sialomucins. Glycobiology. 1993; 3: 437-445.
34. Butler WT. The nature and significance of osteopontin. Connect Tissue Res. 1989; 23: 123-136.
35. Denhardt DT, Guo X. Osteopontin: A protein with diverse functions. FASEB J. 1993; 7: 1475-1482.
36. Maeno Y, Shinzato M, Nagashima S, Rittling SR, Denhardt DT, Uede T, et al. Effect of osteopontin on diarrhea duration and innate immunity in suckling mice infected with a murine rotavirus. Viral Immunol. 2009; 22: 139-144. https://doi.org/10.1089/vim.2008.0054
37. Rollo EE, Hempson SJ, Bansal A, Tsao E, Habib I, Rittling SR, et al. The cytokine osteopontin modulates the severity of rotavirus diarrhea. J Virol. 2005; 79: 3509-3516. https://doi.org/10.1128/JVI.79.6. 3509-3516.2005
38. Mao X, Gu C, Hu H, Tang J, Chen D, Yu B, et al. Dietary Lactobacillus rhamnosus GG Supplementation Improves the Mucosal Barrier Function in the Intestine of Weaned Piglets Challenged by Porcine Rotavirus. PLoS One. 2016; 11: e0146312. https://doi.org/10.1371/journal.pone.0146312
39. Chang RM, Wen LQ, Chang JX, Fu YR, Jiang ZP, et al. Repair of damaged intestinal mucosa in a mouse model of sepsis. World J Emerg Med. 2013; 4: 223-228. https://doi.org/10.5847/wjem.j.1920-8642.2013.03.012
40. Ferrary E, Cohen-Tannoudji M, Pehau-Arnaudet G, Lapillonne A, Athman R, Ruiz T, et al. In vivo, villin is required for Ca2+-dependent F-Actin disruption in intestinal brush borders. J Cell Biol. 1999; 146: 819-830.
41. Ubelmann F, Chamaillard M, El-Marjou F, Simon A, Netter J, Vignjevic D, et al. Enterocyte loss of polarity and gut wound healing rely upon the F-Actin-severing function of villin. Proc Natl Acad Sci U S A. 2013; 110: E1380-1389. https://doi.org/10.1073/pnas.1218446110
42. Ho SB, Dvorak LA, Moor RE, Jacobson AC, Frey MR, Corredor J, et al. Cysteine-rich domains of muc3 intestinal mucin promote cell migration, inhibit apoptosis, and accelerate wound healing. Gastroenterology. 2006; 131: 1501-1517. https://doi.org/10.1053/j.gastro.2006.09.006
43. Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D, et al. Na+-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012; 61: 187-196. https://doi.org/10.2337/db11-1029
44. Wright EM, Turk E, Martin MG. Molecular basis for glucose-galactose malabsorption. Cell Biochem Biophys. 2002; 36: 115-121. https://doi.org/10.1385/CBB:36:2-3:115
45. Gillespie D, Hood K, Bayer A, Carter B, Duncan D, Espinasse A, et al. Antibiotic prescribing and associated diarrhoea: A prospective cohort study of care home residents. Age Ageing. 2015; 44: 853-860. https://doi.org/10.1093/ageing/afv072
46. Mikkelsen KH, Frost M, Bahl MI, Licht TR, Jensen US, Rosenberg J, et al. Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism. PLoS One. 2015; 10: e0142352. https://doi.org/10.1371/journal.pone.0142352
47. More MI, Swidsinski A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosisDa review. Clin Exp Gastroenterol. 2015; 8: 237-255. https://doi. org/10.2147/CEG.S85574
48. Kawahara T, Takahashi T, Oishi K, Tanaka H, Masuda M, Takahashi S, et al. Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model. Microbiol Immunol. 2015; 59: 1-12. https://doi.org/10.1111/1348-0421.12210
49. Brandtzaeg P. Mucosal immunity: integration between mother and the breast-fed infant. Vaccine. 2003; 21: 3382-3388.
50. Kang JY, Lee do K, Ha NJ, Shin HS. Antiviral effects of Lactobacillus ruminis SPM0211 and Bifidobacterium longum SPM1205 and SPM1206 on rotavirus-infected Caco-2 cells and a neonatal mouse model. J Microbiol. 2015; 53: 796-803. https://doi.org/10.1007/s12275-015-5302-2
51. Lee DK, Park JE, Kim MJ, Seo JG, Lee JH, et al. Probiotic bacteria, B. longum and L. acidophilus inhibit infection by rotavirus in vitro and decrease the duration of diarrhea in pediatric patients. Clin Res Hepatol Gastroenterol. 2015; 39: 237-244. https://doi.org/10.1016/j.clinre.2014.09.006
52. Chenoll E, Casinos B, Bataller E, Buesa J, Ramon D, Genoves S, et al. Identification of a Peptide Produced by Bifidobacterium longum CECT 7210 with Antirotaviral Activity. Front Microbiol. 2016; 7: 655. https://doi.org/10.3389/fmicb.2016.00655